Latest Conference Coverage

Expensive Antiseizure Medications Cause for Concern for Patients with Epilepsy: Deepti Zutshi, MD, FAAN

The associate professor of neurology at Wayne State University in Detroit, Michigan, spoke about expensive antiseizure medications for epilepsy along with spending for Medicare and Medicaid at the 2022 AES Annual Meeting. [WATCH TIME: 4 minutes]

XEN1101 Posts Positive Efficacy, Safety in Focal-Onset Epilepsy in Interim Phase 2b Open-Label Data

The investigational therapy from Xenon Pharmaceuticals showed marked reductions in monthly seizure frequency from months 14 to 20, with consistent safety and good retention rates.

Jacksonian Epilepsy and the Jacksonian March: R. Edward Hogan, MD

The professor of neurology at Washington University in St. Louis, and the president of the American Epilepsy Society, shared his perspective on John Hughlings Jackson’s observations of epilepsy in the brain and how it can inform modern practice. [WATCH TIME: 5 minutes]

Transition to Adult Care Is Inconsistent for Patients With Dravet Syndrome, Survey Suggests

A survey conducted in conjunction with the Dravet Syndrome Foundation suggests that many patients with DS do not undergo the transition of care from pediatric to adult neurology providers, with caregivers of those who did expressing some concerns about the process.

Dementia and Active Seizures Reveal Association With Worse Clinical Outcomes

Recent findings presented in a poster at the 2022 AES revealed that higher mortality and shorter lifespans were associated with patients with dementia who have active seizures.

Broad Anti-inflammatory Approaches Feasible for Epilepsy: Nicholas Varvel, PhD

The assistant professor in the department of pharmacology and chemical biology at Emory University School of Medicine spoke about immune cells in epilepsy based on his special lecture at the 2022 AES Annual Meeting. [WATCH TIME: 4 minutes]

Focal Epilepsy Diagnosis Delay Increases Suicidal Ideation Among Youth

A retrospective observation study presented as a poster at the 2022 AES annual meeting revealed that youth with focal epilepsy were more at risk for suicidal ideation when there is a delay in receiving a diagnosis.

Wide Variety Exists for First Antiseizure Medication Prescriptions in Children With Epilepsy

Data from the Pediatric Epilepsy Learning Healthcare System suggest that a variety of factors—including age, preference, insurance, and demographics—affect physician selection of antiseizure medications, with little standardization among this population.

NeurologyLive® Brain Games: December 4, 2022

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Epilepsy Society.

Interdisciplinary Care Teams in Epilepsy Care: Lucretia Long, APRN-CNP

The associate clinical professor of neurology at OSU Wexner Medical Center discussed the state of interdisciplinary care for individuals with epilepsy, and how these care teams operate. [WATCH TIME: 2 minutes]

New Prospective Data on Patients With Dravet Syndrome Inform Outcome Measurements in Trials

Data from the BUTTERFLY study of 36 children with Dravet syndrome have provided 12-month measurements of neurodevelopment, clinical status, quality of life, and executive function. Investigators expressed that these data will help inform future trial outcome measures.

The Pediatric Epilepsy Learning Healthcare System Provides Big Data to Answer Big Questions

Zachary Grinspan, MD, MS, a pediatric epilepsy specialist at Weill Cornell Medicine, in New York City, spoke about the analysis of large amounts of data on pediatric epilepsy at the 2022 American Epilepsy Society Annual Meeting.

Using Semiology to Improve Epilepsy Clinical Trials: Jacqueline French, MD

The professor of neurology at NYU Grossman School of Medicine and chief medical officer of the Epilepsy Foundation discussed the critical need to ensure the proper classification of seizures when enrolling patients in clinical trials. [WATCH TIME: 4 minutes]

Understanding the Safety Profile of Lecanamab: Marwan Sabbagh, MD, FAAN

The behavioral neurologist at the Barrow Neurological Institute provided perspective on the safety profile of lecanemab and the importance of a low incidence of amyloid-related imaging abnormalities. [WATCH TIME: 3 minutes]

Mirtazapine and Carbamazepine Fail to Demonstrate Clinical and Cost Effectiveness as Alzheimer Agitation Treatments

Over a 12-week treatment period, investigators found no significant differences in mean Cohen Mansfield Agitation Inventory scores between mirtazapine and placebo, with similar rates in adverse events.

Shifting the Paradigm of Clinical Research in Alzheimer Disease With the COCOA Trial: Jared Roach, MD, PhD

The senior research scientist at the Institute for Systems Biology spoke about changing the perception of clinical trials for Alzheimer disease research based on the COCOA trial presented at the 2022 CTAD conference. [WATCH TIME: 2 minutes]

Brexpiprazole Continues to Demonstrate Efficacy as Alzheimer Agitation Therapy Across Multiple Phase 3 Trials

Across 3 trials in patients with Alzheimer disease agitation, brexpiprazole doses of 2 or 3 mg/day was safe and showed a statistically significant improvement vs placebo in agitation.

Addressing Unmet Needs of Dementia With Lewy Bodies: James Galvin, MD, MPH

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the treatment differences and unmet needs between dementia with Lewy bodies and Alzheimer disease. [WATCH TIME: 4 minutes]

Behavioral Lifestyle Interventions to Improve Cognitive Outcomes for Alzheimer Disease: Jared Roach, MD, PhD

The senior research scientist at the Institute for Systems Biology spoke about his presentation on multimodal clinical and lifestyle interventions that improve cognitive outcomes at the 2022 CTAD conference. [WATCH TIME: 4 minutes]

Amyloid Copathology Not a Factor in Pharmacodynamic Effect of Irsenontrine in Dementia With Lewy Bodies, Parkinson Disease Dementia

Over a 12-week treatment period, irsenontrine was well tolerated across both amyloid positive and negative patients, with no significant difference in pharmacodynamic responses or change in central nervous system biomarkers.

Targeting Inflammation to Reduce Effects of Alzheimer Disease: RJ Tesi, MD

The president and chief executive officer of INmune Bio detailed the mechanistic advantages of XPro1595 as a potentially therapeutic benefit for patients with Alzheimer disease and dementia. [WATCH TIME: 5 minutes]

Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab

Over a 6-month period, percent change and mean change in brain amyloid levels significantly favored donanemab over aducanumab (Aduhelm; Biogen).

ACI-35.030 and JACI-35.054 Vaccinations Demonstrate Safety in Early Alzheimer Disease

An ongoing phase 1b/2a clinical trial showed that both the ACI-35.030 and JACI-35.054 vaccines are safe as a treatment for patients in the earlier stages of Alzheimer disease, the authors suggested ACI-35.030 suggested as the superior vaccine candidate.

NeuroVoices: Carrie Hersh, DO, MSc, on Applying 2-Stage Models to Improve Disease-Modifying Therapy Selection in MS

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided background on incorporation of real-world methods to optimize treatment selection for multiple sclerosis.

Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses

In the pivotal phase 3 Clarity AD trial, lecanemab (Biogen) demonstrated significant impacts on primary and secondary end points, with additional promising results on biomarker analyses and safety.

Digital Treatment Approach May Help Reduce Healthcare Burden for MS Fatigue: Federica Picariello, PhD

The postdoctoral researcher and health psychologist at King's College London spoke at ECTRIMS 2022 about the digital approach to treating fatigue in multiple sclerosis and the lack of available measurements. [WATCH TIME: 3 minutes]

NeurologyLive® Brain Games: November 27, 2022

CBT as an Effective Mood Therapy for Patients with MS Experiencing Fatigue: Federica Picariello, PhD

The postdoctoral researcher and health psychologist at King's College, London spoke at ECTRIMS 2022 about the relationship between mood and fatigue in patients with MS. [WATCH TIME: 2 minutes]

Future Thoughts on Improving MS Trial Design, Calculations: Carrie Hersh, DO, MSc

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided perspective on how the clinical community can improve trials for multiple sclerosis that help improve treatment decisions. [WATCH TIME: 4 minutes]

Physical Movement Improves Fatigue for Patients with MS: Federica Picariello, PhD

The postdoctoral researcher and health psychologist at King's College, London spoke at ECTRIMS 2022 about the most important aspect for improving fatigue in MS. [WATCH TIME: 4 minutes]